About this trial

Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance

Eligibility criteria

Qualifiers

Willing to provide written and dated informed consent to participate in the study.

Willing and able to comply with the protocol.

Are not on any medication, or supplements which would impact the trial in the opinions of the investigator or Sponsor.

Male or female between 18 and 45 years of age (18.5 kg/m2 ≥ BMI < 30 kg/m2).

Disqualifiers

Subjects having a known allergy or hypersensitivity to any of the ingredients in the investigational products.

Subjects with a history of alcohol and/or other drug abuse in the past year.

Has performed strenuous exercise (rating of perceived exertion ≥ 13) ≤ 48 hours before laboratory visit (Borg, 1982).

Consuming >14 alcoholic drinks per week or > 2 drinks/day in the 48 hours preceding a clinic visit.

Trial design

Treatments tested in this trial

  • Lentil protein hydrolysate
  • Placebo MCC micro-crystalline cellulose

Treatment groups

48 Participants
are divided into 4 treatment groups

Locations

1
Baker Heart and Diabetes Institute3004, MelbourneVictoria, Australia

Sponsors and collaborators

Nuritas Ltd

Lead sponsor

Australian Catholic University

Collaborator

Baker Heart and Diabetes Institute

Collaborator